Uses of compositions comprising a dopamine agonist selected from pramipexole, bromocriptine, cabergoline, pergolide, ropinirole and quinagolide, and an atypical antipsychotic drug selected from clozapine, olanzapine, quetiapine and risperidone
585621 Disclosed is the use of a dopamine agonist in the manufacture of a medicament for preventing or reducing weight gain associated with administration of an atypical antipsychotic drug, wherein the medicament when administered, is administered simultaneously or sequentially with the atypical antipsychotic drug, wherein the dopamine agonist is selected from the group consisting of pramipexole, bromocriptine, cabergoline, pergolide, ropinirole and quinagolide, and wherein the atypical antipsychotic drug is selected form the group consisting of clozapine, olanzapine, quetiapine and risperidone.
